Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$68.62+2.26 (+3.41%)
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Vaxcyte enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Vaxcyte's enterprise value was $8.45B on Nov 11, 2026, against $4.74B a year earlier. Over the last 5 years it ranged from $721.83M to $11.18B, with a median of $3.66B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.45B | +97.0% |
| 2025 | Dec 31, 2025 | $4.29B | -46.4% |
| 2024 | Dec 31, 2024 | $8.01B | +70.1% |
| 2023 | Dec 29, 2023 | $4.71B | +85.2% |
| 2022 | Dec 30, 2022 | $2.54B | +161.6% |
| 2021 | Dec 31, 2021 | $971.62M | +1.6% |
| 2020 | Dec 31, 2020 | $956.68M | – |
See a number that looks wrong?